Lactate dehydrogenase 5: An old friend and a new hope in the war on cancer

Cancer Letters

Volumn 358, Issue 1, 2015, Pages 1-7

  Augoff, Katarzyna ^a   Hryniewicz Jankowska, Anita ^b   Tabola, Renata ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

^b UNIVERSITY OF WROC AW   (Poland)

Author keywords

Aerobic glycolysis; Cancer metabolism; Lactate dehydrogenase 5 (LDH 5)

Indexed keywords

1 HYDROXY 6 PHENYL 4 (TRIFLUOROMETHYL) 1H INDOL 2 CARBOXYLIC ACID; 3 DIHYDROXY 6 METHYL 7 (PHENYLMETHYL)4 PROPYLNAPHTHALENE 1 CARBOXYLIC ACID; 3 [[3 CARBAMOYL 7 (3,5 DIMETHYLISOXAZOL 4 YL) 6 METHOXYQUINOLIN 4 YL]AMINO]BENZOIC ACID; CHINESE GALL EXTRACT; ENZYME INHIBITOR; LACTATE DEHYDROGENASE; LACTATE DEHYDROGENASE 5; LACTATE DEHYDROGENASE 5 INHIBITOR; LACTATE DEHYDROGENASE ISOENZYME; METHYL 1 HYDROXY 6 PHENYL 4 (TRIFLUOROMETHYL) 1H INDOL 2 CARBOXYLATE; PLANT EXTRACT; SPATHOLOBUS SUBERECTUS EXTRACT; TUMOR MARKER; UNCLASSIFIED DRUG; ISOENZYME;

CANCER GROWTH; CANCER RESEARCH; CANCER THERAPY; CHINESE GALL; DRUG ACTIVITY; ENZYME ACTIVITY; ENZYME INHIBITION; GENE EXPRESSION REGULATION; GENE MUTATION; HUMAN; LDHA GENE; MEDICINAL PLANT; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN MODIFICATION; PROTEIN TARGETING; SHORT SURVEY; SPATHOLOBUS SUBERECTUS; BIOSYNTHESIS; CARCINOGENESIS; CITRIC ACID CYCLE; ENZYMOLOGY; GENETICS; GLYCOLYSIS; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASMS; PATHOLOGY;

CARCINOGENESIS; CITRIC ACID CYCLE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOLYSIS; HUMANS; ISOENZYMES; L-LACTATE DEHYDROGENASE; MOLECULAR TARGETED THERAPY; NEOPLASMS;

EID: 84921409248     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.12.035     Document Type: Review

References (96)

1. Dang C.V. Links between metabolism and cancer. Genes Dev 2012, 26(9):877-890.
2. Gatenby R.A., Gillies R.J. Why do cancers have high aerobic glycolysis?. Nat. Rev. Cancer 2004, 4:891-899.
3. Semenza G.L., Jiang B.H., Leung S.W., Passantino R., et al. Hypoxia response elements in the aldolase A, enolase 1, and lactate dehydrogenase A gene promoters contain essential binding sites for hypoxia-inducible factor 1. J. Biol. Chem 1996, 271(51):32529-32537.
4. Shim H., Dolde C., Lewis B.C., Wu C.S., et al. c-Myc transactivation of LDH-A: implications for tumor metabolism and growth. Proc. Natl. Acad. Sci. U.S.A. 1997, 94(13):6658-6663.
5. Sheng S.L., Liu J.J., Dai Y.H., Sun X.G., et al. Knockdown of lactate dehydrogenase A suppresses tumor growth and metastasis of human hepatocellular carcinoma. FEBS J. 2012, 279(20):3898-3910.
6. Krieg A.F., Rosenblum L.J., Henry J.B. Lactate dehydrogenase isoenzymes a comparison of pyruvate-to-lactate and lactate-to-pyruvate assays. Clin. Chem 1967, 13(3):196-203.
7. Goldberg E. Immunochemical specificity of lactate dehydrogenase-X. Proc. Natl. Acad. Sci. U.S.A. 1971, 68(2):349-352.
8. Kopperschläger G., Kirchberger J. Methods for the separation of lactate dehydrogenases and clinical significance of the enzyme. J. Chromatogr. B. Biomed Appl 1996, 684(1-2):25-49.
9. Grosse F., Nasheuer H.P., Scholtissek S., Schomburg U. Lactate dehydrogenase and glyceraldehyde-phosphate dehydrogenase are single-stranded DNA-binding proteins that affect the DNA-polymerase-alpha-primase complex. Eur. J. Biochem 1986, 160(3):459-467.
10. Cooper J.A., Esch F.S., Taylor S.S., Hunter T. Phosphorylation sites in enolase and lactate dehydrogenase utilized by tyrosine protein kinases in vivo and in vitro. J. Biol. Chem 1984, 259(12):7835-7841.
11. Fan J., Hitosugi T., Chung T.W., Xie J., et al. Tyrosine phosphorylation of lactate dehydrogenase A is important for NADH/NAD(+) redox homeostasis in cancer cells. Mol. Cell. Biol 2011, 31(24):4938-4950.
12. Zhao D., Xiong Y., Lei Q.Y., Guan K.L. LDH-A acetylation: implication in cancer. Oncotarget 2013, 4(6):802-803.
13. Zhao D., Zou S.W., Liu Y., Zhou X., et al. Lysine-5 acetylation negatively regulates lactate dehydrogenase A and is decreased in pancreatic cancer. Cancer Cell 2013, 23(4):464-476.
14. Matrisian L.M., Rautmann G., Magun B.E., Breathnach R. Epidermal growth factor or serum stimulation of rat fibroblasts induces an elevation in mRNA levels for lactate dehydrogenase and other glycolytic enzymes. Nucleic Acids Res 1985, 13(3):711-726.
15. Boussouar F., Benahmed M. Epidermal growth factor regulates glucose metabolism through lactate dehydrogenase A messenger ribonucleic acid expression in cultured porcine Sertoli cells. Biol. Reprod 1999, 61(4):1139-1145.
16. Boussouar F., Grataroli R., Ji J., Benahmed M. Tumor necrosis factor-alpha stimulates lactate dehydrogenase A expression in porcine cultured sertoli cells: mechanisms of action. Endocrinology 1999, 140(7):3054-3062.
17. Tian D., Huang D., Brown R.C., Jungmann R.A. Protein kinase A stimulates binding of multiple proteins to a U-rich domain in the 3'-untranslated region of lactate dehydrogenase A mRNA that is required for the regulation of mRNA stability. J. Biol. Chem 1998, 273(43):28454-28460.
18. Huang D., Jungmann R.A. Transcriptional regulation of the lactate dehydrogenase A subunit gene by the phorbol ester 12-O-tetradecanoylphorbol-13-acetate. Mol. Cell. Endocrinol 1995, 108(1-2):87-94.
19. Short M.L., Huang D., Milkowski D.M., Short S., et al. Analysis of the rat lactate dehydrogenase A subunit gene promoter/regulatory region. Biochem. J. 1994, 304(Pt 2):391-398.
20. Zhong H., De Marzo A.M., Laughner E., Lim M., et al. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res 1999, 59(22):5830-5835.
21. Koukourakis M.I., Giatromanolaki A., Sivridis E., Bougioukas G., et al. Lactate dehydrogenase-5 (LDH-5) overexpression in non-small-cell lung cancer tissues is linked to tumour hypoxia, angiogenic factor production and poor prognosis. Br. J. Cancer 2003, 89(5):877-885. Tumour and Angiogenesis Research Group.
22. Kolev Y., Uetake H., Takagi Y., Sugihara K. Lactate dehydrogenase-5 (LDH-5) expression in human gastric cancer: association with hypoxia-inducible factor (HIF-1alpha) pathway, angiogenic factors production and poor prognosis. Ann. Surg. Oncol 2008, 15(8):2336-2344.
23. Listowski M.A., Heger E., Bogusławska D.M., Machnicka B., et al. microRNAs: fine tuning of erythropoiesis. Cell. Mol. Biol. Lett 2013, 18(1):34-46.
24. Madanecki P., Kapoor N., Bebok Z., Ochocka R., et al. Regulation of angiogenesis by hypoxia: the role of microRNA. Cell. Mol. Biol. Lett 2013, 18(1):47-57.
25. Davis-Dusenbery B.N., Hata A. MicroRNA in cancer: the involvement of aberrant MicroRNA biogenesis regulatory pathways. Genes Cancer 2010, 1(11):1100-1114.
26. Chen B., Li H., Zeng X., Yang P., Liu X., et al. Roles of microRNA on cancer cell metabolism. J. Transl. Med 2012, 10:2-28.
27. Kinoshita T., Nohata N., Yoshino H., Hanazawa T., et al. Tumor suppressive microRNA-375 regulates lactate dehydrogenase B in maxillary sinus squamous cell carcinoma. Int. J. Oncol 2012, 40(1):85-93.
28. Kaller M., Liffers S.T., Oeljeklaus S., Kuhlmann K., et al. Genome-wide characterization of miR-34a induced changes in protein and mRNA expression by a combined pulsed SILAC and microarray analysis. Mol. Cell. Proteomics 2011, 10(8). M111.010462.
29. Lodygin D., Tarasov V., Epanchintsev A., Berking C., et al. Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer. Cell Cycle 2008, 7(16):2591-2600.
30. Srivastava N.K., Yadav R., Pradhan S. Metabolic myopathies; clinical, biochemical, genetic and histopathological basis of diagnosis. Ann. Neurosci 2005, 12(4):87-98.
31. Merkle S., Favor J., Graw J., Hornhardt S., Pretsch W. Hereditary lactate dehydrogenase A-subunit deficiency as cause of early postimplantation death of homozygotes in Mus musculus. Genetics 1992, 131(2):413-421.
32. Miyajima H., Takahashi Y., Kaneko E. Characterization of the oxidative metabolism in lactate dehydrogenase A deficiency. Intern. Med 1995, 34(6):502-506.
33. Yamagata M., Hasuda K., Stamato T., Tannock I.F. The contribution of lactic acid to acidification of tumours: studies of variant cells lacking lactate dehydrogenase. Br. J. Cancer 1998, 77(11):1726-1731.
34. Ferraris A.M., Giuntini P., Gaetani G.F. Serum lactic dehydrogenase as a prognostic tool for non-Hodgkin lymphomas. Blood 1979, 54(4):928-932.
35. García R., Hernández J.M., Caballero M.D., González M., et al. Serum lactate dehydrogenase level as a prognostic factor in Hodgkin's disease. Br. J. Cancer 1993, 68(6):1227-1231.
36. Bouafia F., Drai J., Bienvenu J., Thieblemont C., et al. Profiles and prognostic values of serum LDH isoenzymes in patients with haematopoietic malignancies. Bull. Cancer 2004, 91(7-8):E229-E240.
37. Gkotzamanidou M., Kastritis E., Gavriatopoulou M.R., Nikitas N., et al. Increased serum lactate dehydrongenase should be included among the variables that define very-high-risk multiple myeloma. Clin. Lymphoma Myeloma Leuk 2011, 11(5):409-413.
38. Lu R., Jiang M., Chen Z., Xu X., et al. Lactate dehydrogenase 5 expression in non-Hodgkin lymphoma is associated with the induced hypoxia regulated protein and poor prognosis. PLoS ONE 2013, 8(9):e74853.
39. Hermes A., Gatzemeier U., Waschki B., Reck M. Lactate dehydrogenase as prognostic factor in limited and extensive disease stage small cell lung cancer - a retrospective single institution analysis. Respir. Med 2010, 104(12):1937-1942.
40. Terpos E., Katodritou E., Roussou M., Pouli A., et al. High serum lactate dehydrogenase adds prognostic value to the international myeloma staging system even in the era of novel agents. Eur. J. Haematol 2010, 85(2):114-119.
41. Scartozzi M., Giampieri R., Maccaroni E., Del Prete M., et al. Pre-treatment lactate dehydrogenase levels as predictor of efficacy of first-line bevacizumab-based therapy in metastatic colorectal cancer patients. Br. J. Cancer 2012, 106(5):799-804.
42. Jin Y., Ye X., Shao L., Lin B.C., et al. Serum lactic dehydrogenase strongly predicts survival in metastatic nasopharyngeal carcinoma treated with palliative chemotherapy. Eur. J. Cancer 2013, 49(7):1619-1626.
43. Wan X.B., Wei L., Li H., Dong M., et al. High pretreatment serum lactate dehydrogenase level correlates with disease relapse and predicts an inferior outcome in locally advanced nasopharyngeal carcinoma. Eur. J. Cancer 2013, 49(10):2356-2364.
44. Yin C., Jiang C., Liao F., Rong Y., et al. Initial LDH level can predict the survival benefit from bevacizumab in the first-line setting in Chinese patients with metastatic colorectal cancer. Onco Targets Ther 2014, 7:1415-1422.
45. Scartozzi M., Faloppi L., Bianconi M., Giampieri R., et al. The role of LDH serum levels in predicting global outcome in HCC patients undergoing TACE: implications for clinical management. PLoS ONE 2012, 7(3):e32653.
46. Faloppi L., Scartozzi M., Bianconi M., Svegliati Baroni G., et al. The role of LDH serum levels in predicting global outcome in HCC patients treated with sorafenib: implications for clinical management. BMC Cancer 2014, 14(110):2-8.
47. Ishibe T. Prognostic usefulness of serum lactic dehydrogenase and its fifth isoenzyme levels in carcinoma of the prostate. Int. Urol. Nephrol 1976, 8(3):221-225.
48. Armstrong A.J., George D.J., Halabi S. Serum lactate dehydrogenase predicts for overall survival benefit in patients with metastatic renal cell carcinoma treated with inhibition of mammalian target of rapamycin. J. Clin. Oncol 2012, 30(27):3402-3407.
49. Lossos I.S., Intrator O., Berkman N., Breuer R. Lactate dehydrogenase isoenzyme analysis for the diagnosis of pleural effusion in haemato-oncological patients. Respir. Med 1999, 93(5):338-341.
50. Sevinc A., Sari R., Fadillioglu E. The utility of lactate dehydrogenase isoenzyme pattern in the diagnostic evaluation of malignant and nonmalignant ascites. J. Natl Med. Assoc 2005, 97(1):79-84.
51. Nishikawa A., Tanaka T., Takeuchi T., Fujihiro S., Mori H. The diagnostic significance of lactate dehydrogenase isoenzymes in urinary cytology. Br. J. Cancer 1991, 63(5):819-821.
52. Buamah P.K., Skillen A.W. Lactate dehydrogenase isoenzyme 1 activity in sera of patients with ovarian cancer. Clin. Chem 1990, 36(4):707-708.
53. von Eyben F.E. A systematic review of lactate dehydrogenase isoenzyme 1 and germ cell tumors. Clin. Biochem 2001, 34(6):441-454.
54. Timperley W.R. Lactate dehydrogenase isoenzymes in tumours of the nervous system. Acta Neuropathol 1971, 19(1):20-24.
55. Caltrider N.C., Lehman J.M. Changes in lactate dehydrogenase enzyme pattern in Chinese hamster cells infected and transformed with Simian virus 40. Cancer Res 1975, 35(8):1944-1949.
56. Wang Z.Y., Loo T.Y., Shen J.G., Wang N., et al. LDH-A silencing suppresses breast cancer tumorigenicity through induction of oxidative stress mediated mitochondrial pathway apoptosis. Breast Cancer Res. Treat 2012, 131(3):791-800.
57. Nishitani K., Namba M., Kimoto T. Lactate dehydrogenase isozyme patterns of normal human fibroblasts and their in vitro-transformed counterparts obtained by treatment with CO-60 gamma-rays, SV40 or 4-nitroquinoline 1-oxide. Gann 1981, 72(2):300-304.
58. Langvad E., Jemec B. Prediction of local recurrence in colorectal carcinoma: an LDH isoenzymatic assay. Br. J. Cancer 1975, 31(6):661-664.
59. Carda-Abella P., Perez-Cuadrado S., Lara-Baruque S., Gil-Grande L., Nuñez-Puertas A. LDH isoenzyme patterns in tumors, polyps, and uninvolved mucosa of human cancerous colon. Cancer 1982, 49(1):80-83.
60. Kayser G., Kassem A., Sienel W., Schulte-Uentrop L., et al. Lactate-dehydrogenase 5 is overexpressed in non-small cell lung cancer and correlates with the expression of the transketolase-like protein 1. Diagn. Pathol 2010, 5:22.
61. Kim H.S., Lee H.E., Yang H.K., Kim W.H. High lactate dehydrogenase 5 expression correlates with high tumoral and stromal vascular endothelial growth factor expression in gastric cancer. Pathobiology 2013, 81(2):78-85.
62. Grimm M., Alexander D., Munz A., Hoffmann J., Reinert S. Increased LDH5 expression is associated with lymph node metastasis and outcome in oral squamous cell carcinoma. Clin. Exp. Metastasis 2013, 30(4):529-540.
63. Yao F., Zhao T., Zhong C., Zhu J., Zhao H. LDHA is necessary for the tumorigenicity of esophageal squamous cell carcinoma. Tumour Biol 2013, 34(1):25-31.
64. Rong Y., Wu W., Ni X., Kuang T., Jin D., et al. Lactate dehydrogenase A is overexpressed in pancreatic cancer and promotes the growth of pancreatic cancer cells. Tumour Biol 2013, 34(3):1523-1530.
65. Rizwan A., Serganova I., Khanin R., Karabeber H., et al. Relationships between LDH-A, lactate, and metastases in 4T1 breast tumors. Clin. Cancer Res 2013, 19(18):5158-5169.
66. Yu Y., Liao M., Liu R., Chen J., et al. Overexpression of lactate dehydrogenase-A in human intrahepatic cholangiocarcinoma: its implication for treatment. World J. Surg. Oncol 2014, 12(78):1-7.
67. Lewis B., Morson B.C., February A.W., Jones J.H., Misiewicz J.J. Abnormal lactic dehydrogenase isoenzyme patterns in ulcerative colitis with precancerous change. Gut 1971, 12(1):16-19.
68. Latner A.L., Turner D.M., Way S.A. Enzyme and isoenzyme studies in preinvasive carcinoma of the cervix. Lancet 1966, 2(7468):814-816.
69. Langvad E. Lactate dehydrogenase isoenzyme patterns in bronchogenic carcinoma. Eur. J. Cancer 1968, 4(1):107-115.
70. Woollams R., Barratt P.J., Orwell R.L., Piper D.W. LDH isoenzyme pattern of uninvolved gastric mucosa of patients with gastric carcinoma and benign gastric disease. Digestion 1976, 14(1):20-28.
71. Mate J., Pajares J.M., Moreno-Otero R., Perez-Cuadrado S. Abnormal lactic dehydrogenase patterns in carcinoma of stomach and in peritumoral tissues. Digestion 1978, 17(5):377-382.
72. Koukourakis M.I., Giatromanolaki A., Sivridis E., Gatter K.C., Harris A.L. Lactate dehydrogenase 5 expression in operable colorectal cancer: strong association with survival and activated vascular endothelial growth factor pathway - a report of the Tumour Angiogenesis Research Group. J. Clin. Oncol 2006, 24(26):4301-4308. Tumour Angiogenesis Research Group.
73. Chai H., Brown R.E. Field effect in cancer-an update. Ann. Clin. Lab. Sci 2009, 39(4):331-337.
74. Augoff K., Grabowski K., Wozniak Z., Taboła R., Chrzanowska T. The A/B ratio of lactate dehydrogenase (LDH) subunits in combination with Ki-67 labelling index (LI Ki-67) in relation to clinicopathological variables and prognosis in gastric cancer. Case Rep. Clin. Pract. Rev 2004, 5:108-113.
75. Sattler U.S., Meyer S.S., Quennet V., Hoerner C., et al. Glycolytic metabolism and tumour response to fractionated irradiation. Radiother. Oncol 2010, 94(1):102-109.
76. Dhup S., Dadhich R.K., Porporato P.E., Sonveaux P. Multiple biological activities of lactic acid in cancer: influences on tumor growth, angiogenesis and metastasis. Curr. Pharm. Des 2012, 18(10):1319-1330.
77. Fantin V.R., St-Pierre J., Leder P. Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell 2006, 9(6):425-434.
78. Le A., Cooper C.R., Gouw A.M., Dinavahi R., Maitra A., et al. Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression. Proc. Natl. Acad. Sci. U.S.A. 2010, 107(5):2037-2042.
79. Langhammer S., Najjar M., Hess-Stumpp H., Thierauch K.H. LDH-A influences hypoxia-inducible factor 1α (HIF1 α) and is critical for growth of HT29 colon carcinoma cells in vivo. Target Oncol 2011, 6(3):155-162.
80. Xie H., Hanai J., Ren J.G., Kats L., et al. Targeting lactate dehydrogenase-a inhibits tumorigenesis and tumor progression in mouse models of lung cancer and impacts tumor-initiating cells. Cell Metab 2014, 19(5):795-809.
81. Granchi C., Calvaresi E.C., Tuccinardi T., Paterni I., et al. Assessing the differential action on cancer cells of LDH-A inhibitors based on the N-hydroxyindole-2-carboxylate (NHI) and malonic (Mal) scaffolds. Org. Biomol. Chem 2013, 11(38):6588-6596.
82. Farabegoli F., Vettraino M., Manerba M., Fiume L., et al. Galloflavin, a new lactate dehydrogenase inhibitor, induces the death of human breast cancer cells with different glycolytic attitude by affecting distinct signaling pathways. Eur. J. Pharm. Sci 2012, 47(4):729-738.
83. Zhou M., Zhao Y., Ding Y., Liu H., et al. Warburg effect in chemosensitivity: targeting lactate dehydrogenase-A re-sensitizes taxol-resistant cancer cells to taxol. Mol. Cancer 2010, 9:33.
84. Zhai X., Yang Y., Wan J., Zhu R., Wu Y. Inhibition of LDH-A by oxamate induces G2/M arrest, apoptosis and increases radiosensitivity in nasopharyngeal carcinoma cells. Oncol. Rep 2013, 6:2983-2991.
85. Yang Y., Su D., Zhao L., Zhang D., et al. Different effects of LDH-A inhibition by oxamate in non-small cell lung cancer cells. Oncotarget 2014, 2620 [pii].
86. Fiume L., Vettraino M., Carnicelli D., Arfilli V., et al. Galloflavin prevents the binding of lactate dehydrogenase A to single stranded DNA and inhibits RNA synthesis in cultured cells. Biochem. Biophys. Res. Commun 2013, 430(2):466-469.
87. Maftouh M., Avan A., Sciarrillo R., Granchi C., et al. Synergistic interaction of novel lactate dehydrogenase inhibitors with gemcitabine against pancreatic cancer cells in hypoxia. Br. J. Cancer 2014, 110(1):172-182.
88. Allison S.J., Knight J.R., Granchi C., Rani R., et al. Identification of LDH-A as a therapeutic target for cancer cell killing via (i) p53/NAD(H)-dependent and (ii) p53-independent pathways. Oncogenesis 2014, 3:e102.
89. Miskimins W.K., Ahn H.J., Kim J.Y., Ryu S., et al. Synergistic anti-cancer effect of phenformin and oxamate. PLoS ONE 2014, 9(1):e85576.
90. T. O'Brien, H. Purkey, A. Hitz, D. Peterson, etal., Abstract 964: inhibiting glycolysis with an LDHA inhibitor: a new solution to an old problem, Proceedings: AACR Annual Meeting, April 5-9, 2014; San Diego, CA, 2014.
91. Dragovich P.S., Fauber B.P., Boggs J., Chen J., et al. Identification of substituted 3-hydroxy-2-mercaptocyclohex-2-enones as potent inhibitors of human lactate dehydrogenase. Bioorg. Med. Chem. Lett 2014, 24(16):3764-3771.
92. Deiab S., Mazzio E., Messeha S., Mack N., Soliman K.F.A. High-throughput screening to identify plant derived human LDH-A inhibitors. Eur. J. Med. Plants 2013, 3(4):603-615.
93. Wang Z., Wang D., Han S., Wang N., et al. Bioactivity-guided identification and cell signaling technology to delineate the lactate dehydrogenase A inhibition effects of Spatholobus suberectus on breast cancer. PLoS ONE 2013, 8(2):e56631.
94. Ward R.A., Brassington C., Breeze A.L., Caputo A., et al. Design and synthesis of novel lactate dehydrogenase A inhibitors by fragment-based lead generation. J. Med. Chem 2012, 55(7):3285-3306.
95. Kohlmann A., Zech S.G., Li F., Zhou T., et al. Fragment growing and linking lead to novel nanomolar lactate dehydrogenase inhibitors. J. Med. Chem 2013, 56(3):1023-1040.
96. Shi Y., Pinto B.M. Human lactate dehydrogenase a inhibitors: a molecular dynamics investigation. PLoS ONE 2014, 9(1):e86365.